Furthermore, it has been demonstrated that concomitant mutations in KRAS and STK11 confer poor survival in lung adenocarcinoma patients [153] but their role in response to different kinds of treatments, including immunotherapy, need to be further elucidated. Here, KRAS is linked to lung adenocarcinoma.